201 related articles for article (PubMed ID: 12824206)
1. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
Li CI; Malone KE; Porter PL; Weiss NS; Tang MT; Cushing-Haugen KL; Daling JR
JAMA; 2003 Jun; 289(24):3254-63. PubMed ID: 12824206
[TBL] [Abstract][Full Text] [Related]
2. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study.
Williams LA; Nichols HB; Hoadley KA; Tse CK; Geradts J; Bell ME; Perou CM; Love MI; Olshan AF; Troester MA
Cancer Causes Control; 2018 Jan; 29(1):25-32. PubMed ID: 29124544
[TBL] [Abstract][Full Text] [Related]
3. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
Clelland EN; Rothschild HT; Patterson A; Molina-Vega J; Kaur M; Symmans WF; Schwartz CJ; Chien AJ; Benz CC; Mukhtar RA
Breast Cancer Res Treat; 2023 Nov; 202(2):367-375. PubMed ID: 37500962
[TBL] [Abstract][Full Text] [Related]
4. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
Liu Y; West R; Weber JD; Colditz GA
Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis.
Liu J; Chen K; Mao K; Su F; Liu Q; Jacobs LK
Oncotarget; 2016 Feb; 7(5):6063-73. PubMed ID: 26515602
[TBL] [Abstract][Full Text] [Related]
6. First results of hormone receptors' status in Malagasy women with invasive breast cancer.
Hasiniatsy NR; Vololonantenaina CR; Rabarikoto HF; Razafimanjato N; Ranoharison HD; Rakotoson JL; Samison LH; Rafaramino F
Pan Afr Med J; 2014; 17():153. PubMed ID: 25120866
[TBL] [Abstract][Full Text] [Related]
7. Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 Apr; 120(7):1026-34. PubMed ID: 24515648
[TBL] [Abstract][Full Text] [Related]
8. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
Milne RL; Goode EL; García-Closas M; Couch FJ; Severi G; Hein R; Fredericksen Z; Malats N; Zamora MP; Arias Pérez JI; Benítez J; Dörk T; Schürmann P; Karstens JH; Hillemanns P; Cox A; Brock IW; Elliot G; Cross SS; Seal S; Turnbull C; Renwick A; Rahman N; Shen CY; Yu JC; Huang CS; Hou MF; Nordestgaard BG; Bojesen SE; Lanng C; Grenaker Alnæs G; Kristensen V; Børrensen-Dale AL; Hopper JL; Dite GS; Apicella C; Southey MC; Lambrechts D; Yesilyurt BT; Floris G; Leunen K; Sangrajrang S; Gaborieau V; Brennan P; McKay J; Chang-Claude J; Wang-Gohrke S; Radice P; Peterlongo P; Manoukian S; Barile M; Giles GG; Baglietto L; John EM; Miron A; Chanock SJ; Lissowska J; Sherman ME; Figueroa JD; Bogdanova NV; Antonenkova NN; Zalutsky IV; Rogov YI; Fasching PA; Bayer CM; Ekici AB; Beckmann MW; Brenner H; Müller H; Arndt V; Stegmaier C; Andrulis IL; Knight JA; Glendon G; Mulligan AM; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Meindl A; Heil J; Bartram CR; Schmutzler RK; Thomas GD; Hoover RN; Fletcher O; Gibson LJ; dos Santos Silva I; Peto J; Nickels S; Flesch-Janys D; Anton-Culver H; Ziogas A; Sawyer E; Tomlinson I; Kerin M; Miller N; Schmidt MK; Broeks A; Van 't Veer LJ; Tollenaar RA; Pharoah PD; Dunning AM; Pooley KA; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Jakubowska A; Lubinski J; Jaworska K; Durda K; Kang D; Yoo KY; Noh DY; Ahn SH; Hunter DJ; Hankinson SE; Kraft P; Lindstrom S; Chen X; Beesley J; Hamann U; Harth V; Justenhoven C; ; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Hooning M; Hollestelle A; Oldenburg RA; Tilanus-Linthorst M; Khusnutdinova E; Bermisheva M; Prokofieva D; Farahtdinova A; Olson JE; Wang X; Humphreys MK; Wang Q; Chenevix-Trench G; ; ; Easton DF
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2222-31. PubMed ID: 21795498
[TBL] [Abstract][Full Text] [Related]
9. Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study.
Adams SA; Matthews CE; Hebert JR; Moore CG; Cunningham JE; Shu XO; Fulton J; Gao Y; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1170-8. PubMed ID: 16775177
[TBL] [Abstract][Full Text] [Related]
10. Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients.
McCarthy AM; McGuire E; Bristol M; Fredricks T; Domchek SM; Armstrong K
Cancer Epidemiol; 2013 Oct; 37(5):601-5. PubMed ID: 23810747
[TBL] [Abstract][Full Text] [Related]
11. Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry.
Work ME; John EM; Andrulis IL; Knight JA; Liao Y; Mulligan AM; Southey MC; Giles GG; Dite GS; Apicella C; Hibshoosh H; Hopper JL; Terry MB
Br J Cancer; 2014 Mar; 110(5):1367-77. PubMed ID: 24548865
[TBL] [Abstract][Full Text] [Related]
12. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
[TBL] [Abstract][Full Text] [Related]
13. Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.
Rusner C; Wolf K; Bandemer-Greulich U; Engel J; Stegmaier C; Holleczek B; Schubert-Fritschle G; Tillack A; Stang A
Breast Cancer Res; 2014 Oct; 16(5):452. PubMed ID: 25277819
[TBL] [Abstract][Full Text] [Related]
14. Is There a Special Role for Ovarian Hormones in the Pathogenesis of Lobular Carcinoma?
Flaherty RL; Sflomos G; Brisken C
Endocrinology; 2024 Mar; 165(5):. PubMed ID: 38551031
[TBL] [Abstract][Full Text] [Related]
15. Chronic long-term exposure to cadmium air pollution and breast cancer risk in the French E3N cohort.
Amadou A; Praud D; Coudon T; Danjou AMN; Faure E; Leffondré K; Le Romancer M; Severi G; Salizzoni P; Mancini FR; Fervers B
Int J Cancer; 2020 Jan; 146(2):341-351. PubMed ID: 30851122
[TBL] [Abstract][Full Text] [Related]
16. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.
Figueroa JD; Garcia-Closas M; Humphreys M; Platte R; Hopper JL; Southey MC; Apicella C; Hammet F; Schmidt MK; Broeks A; Tollenaar RA; Van't Veer LJ; Fasching PA; Beckmann MW; Ekici AB; Strick R; Peto J; dos Santos Silva I; Fletcher O; Johnson N; Sawyer E; Tomlinson I; Kerin M; Burwinkel B; Marme F; Schneeweiss A; Sohn C; Bojesen S; Flyger H; Nordestgaard BG; Benítez J; Milne RL; Ignacio Arias J; Zamora MP; Brenner H; Müller H; Arndt V; Rahman N; Turnbull C; Seal S; Renwick A; Brauch H; Justenhoven C; Brüning T; ; Chang-Claude J; Hein R; Wang-Gohrke S; Dörk T; Schürmann P; Bremer M; Hillemanns P; Nevanlinna H; Heikkinen T; Aittomäki K; Blomqvist C; Bogdanova N; Antonenkova N; Rogov YI; Karstens JH; Bermisheva M; Prokofieva D; Gantcev SH; Khusnutdinova E; Lindblom A; Margolin S; Chenevix-Trench G; Beesley J; Chen X; ; Mannermaa A; Kosma VM; Soini Y; Kataja V; Lambrechts D; Yesilyurt BT; Chrisiaens MR; Peeters S; Radice P; Peterlongo P; Manoukian S; Barile M; Couch F; Lee AM; Diasio R; Wang X; Giles GG; Severi G; Baglietto L; Maclean C; Offit K; Robson M; Joseph V; Gaudet M; John EM; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Andrulis I; Knight JA; Mulligan AM; O'Malley FP; Brinton LA; Sherman ME; Lissowska J; Chanock SJ; Hooning M; Martens JW; van den Ouweland AM; Collée JM; Hall P; Czene K; Cox A; Brock IW; Reed MW; Cross SS; Pharoah P; Dunning AM; Kang D; Yoo KY; Noh DY; Ahn SH; Jakubowska A; Lubinski J; Jaworska K; Durda K; Sangrajrang S; Gaborieau V; Brennan P; McKay J; Shen CY; Ding SL; Hsu HM; Yu JC; Anton-Culver H; Ziogas A; Ashworth A; Swerdlow A; Jones M; Orr N; Trentham-Dietz A; Egan K; Newcomb P; Titus-Ernstoff L; Easton D; Spurdle AB
Hum Mol Genet; 2011 Dec; 20(23):4693-706. PubMed ID: 21852249
[TBL] [Abstract][Full Text] [Related]
17. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.
Munsell MF; Sprague BL; Berry DA; Chisholm G; Trentham-Dietz A
Epidemiol Rev; 2014; 36(1):114-36. PubMed ID: 24375928
[TBL] [Abstract][Full Text] [Related]
18. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.
Neta G; Anderson WF; Gilbert E; Berrington A
Breast Cancer Res Treat; 2012 Feb; 131(3):1021-7. PubMed ID: 22015617
[TBL] [Abstract][Full Text] [Related]
19. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Zheng YZ; Wang L; Hu X; Shao ZM
Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
[TBL] [Abstract][Full Text] [Related]
20. Hormone therapy and fatal breast cancer.
Norman SA; Weber AL; Localio AR; Marchbanks PA; Ursin G; Strom BL; Weiss LK; Burkman RT; Bernstein L; Deapen DM; Folger SG; Simon MS; Nadel MR
Pharmacoepidemiol Drug Saf; 2010 May; 19(5):440-7. PubMed ID: 20336635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
